Myelofibrosis Treatment in United Arab Emirates

What is Myelofibrosis?

Myelofibrosis is a chronic blood cancer and myeloproliferative neoplasm in which abnormal blood-forming cells and changes in the bone marrow environment cause progressive bone marrow fibrosis. As normal blood-cell production becomes impaired, patients may develop anemia, low platelet counts or abnormal white blood-cell counts. The spleen and liver may begin producing blood cells outside the bone marrow, enlarging these organs. Myelofibrosis may develop on its own as primary myelofibrosis or occur after another myeloproliferative neoplasm such as polycythemia vera or essential thrombocythemia.

What is the Importance of Timely Treatment?

Timely diagnosis and risk assessment are important because myelofibrosis can progress differently from one person to another. Some patients have stable disease and require regular monitoring, while others develop significant anemia, thrombocytopenia, symptomatic splenomegaly, constitutional symptoms or progression to an advanced phase of disease. Early specialist assessment helps determine disease risk, monitor blood counts and symptoms, manage complications and identify patients who may be candidates for potentially disease-modifying treatment such as allogeneic stem-cell transplantation.

What are the Common Symptoms of Myelofibrosis?

• Persistent fatigue and weakness
• Shortness of breath, particularly with activity
• Pale skin due to anemia
• Unexplained weight loss
• Fever or night sweats
• Loss of appetite
• Bone or muscle pain
• Abdominal fullness or discomfort due to an enlarged spleen
• Feeling full after eating a small amount
• Easy bruising or bleeding
• Frequent infections in some patients
• Itching
• Reduced exercise tolerance

Causes and Risk Factors of Myelofibrosis

Causes

• Myelofibrosis develops when abnormal blood-forming stem or progenitor cells acquire genetic changes that promote uncontrolled or abnormal blood-cell production and release inflammatory signals that alter the bone marrow environment.
• Mutations in genes such as JAK2, CALR, and MPL are commonly associated with myelofibrosis, although some patients lack these driver mutations.
• Primary myelofibrosis develops independently, while secondary myelofibrosis can develop after polycythemia vera or essential thrombocythemia.

Risk Factors

• Increasing age
• Presence of an underlying myeloproliferative neoplasm such as polycythemia vera or essential thrombocythemia
• Certain acquired genetic mutations
• Previous treatment or disease-related factors associated with secondary myelofibrosis
• Certain adverse molecular or cytogenetic features associated with higher-risk disease

Latest Research and Technologies in the Treatment of Myelofibrosis in the United Arab Emirates

• Current myelofibrosis research is focused on improving symptom and spleen control, treating anemia and developing therapies that may alter disease progression. JAK inhibitors remain an important targeted treatment approach, while newer and investigational therapies are being studied for patients with anemia, thrombocytopenia, inadequate response or intolerance to existing treatments. Clinical research is also evaluating combinations of targeted therapies and JAK inhibitor approaches alongside allogeneic hematopoietic stem-cell transplantation.